MONTREAL, QUEBEC--(MARKET WIRE)--Jul 10, 2007 -- ProMetic Life Sciences Inc. (Toronto:PLI.TO - News) (“ProMetic”) announces preliminary data from a Phase Ib/II trial with its orally active drug PBI-1402 for the treatment of chemotherapy-induced anemia (CIA). Data highlights include:
